There are two key components - BDNF and its receptor tropomyosin receptor kinase B (TrkB) both of which are fundamental not only in understanding the pathophysiology of depression but also in discovering novel therapeutic agents to treat depression. We now know that BDNF is responsible for significant neuroplastic changes that lead to the improvement of depressive symptoms [9]. This evidence concerns the gene NTRK2 and major depressive disorder.